Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Thomas Weisel Keeps Outperform on Santarus


Thomas Weisel keeps the outperform rating on Santarus (SNTS).

Analyst Donald Ellis says Santarus expects to launch its new Rapinex product in the fourth quarter, ahead of his first-half 2005 estimate. He notes the 230-member salesforce will detail Rapinex to high-prescribing physicians in treating gastrointestinal disorders. He expects FDA approval of 40 mg Rapinex powder-for-suspension by year end.

Ellis says the company's immediate-release, proton pump inhibitor technology provides a more rapid onset of action than the ones currently on the market. He maintains the 48 cents second-quarter loss, and the $2.48 2004 loss estimates until he has a better grasp on launch quantities.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus